| First Author | Mayca Pozo F | Year | 2021 |
| Journal | Sci Adv | Volume | 7 |
| Issue | 38 | Pages | eabg6908 |
| PubMed ID | 34524844 | Mgi Jnum | J:311174 |
| Mgi Id | MGI:6766279 | Doi | 10.1126/sciadv.abg6908 |
| Citation | Mayca Pozo F, et al. (2021) MYO10 drives genomic instability and inflammation in cancer. Sci Adv 7(38):eabg6908 |
| abstractText | Genomic instability is a hallmark of human cancer; yet the underlying mechanisms remain poorly understood. Here, we report that the cytoplasmic unconventional Myosin X (MYO10) regulates genome stability, through which it mediates inflammation in cancer. MYO10 is an unstable protein that undergoes ubiquitin-conjugating enzyme H7 (UbcH7)/β-transducin repeat containing protein 1 (β-TrCP1)âdependent degradation. MYO10 is upregulated in both human and mouse tumors and its expression level predisposes tumor progression and response to immune therapy. Overexpressing MYO10 increased genomic instability, elevated the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING)âdependent inflammatory response, and accelerated tumor growth in mice. Conversely, depletion of MYO10 ameliorated genomic instability and reduced the inflammation signaling. Further, inhibiting inflammation or disrupting Myo10 significantly suppressed the growth of both human and mouse breast tumors in mice. Our data suggest that MYO10 promotes tumor progression through inducing genomic instability, which, in turn, creates an immunogenic environment for immune checkpoint blockades. |
